About this item:
427 Views | 539 Downloads
Author Notes:
Correspondence should be addressed to Thais Federici, tfederi@emory.edu
Academic Editor: Changiz Geula
The authors acknowledge Kenneth and Angela Baker for inspiring this paper.
Thank you for your service and heartfelt commitment to promoting awareness, encouraging research, and fostering hope for ALS.
They also acknowledge the Emory University ALS Center for remaining committed to excellence in patient care.
Subject:
Pain in Amyotrophic Lateral Sclerosis: A Neglected Aspect of Disease
Abstract:
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder marked by progressive loss of motor neurons, muscle wasting, and respiratory dysfunction. With disease progression, secondary symptoms arise creating new problematic conditions for ALS patients. Amongst these is pain. Although not a primary consequence of disease, pain occurs in a substantial number of individuals. Yet, studies investigating its pathomechanistic properties in the ALS patient are lacking. Therefore, more exploratory efforts into its scope, severity, impact, and treatment should be initiated. Several studies investigating the use of Clostridial neurotoxins for the reduction of pain in ALS patients suggest the potential for a neural specific approach involving focal drug delivery. Gene therapy represents a way to accomplish this. Therefore, the use of viral vectors to express transgenes that modulate the nociceptive cascade could prove to be an effective way to achieve meaningful benefit in conditions of pain in ALS.
Copyright information:
© 2011 Chalonda R. Handy et al.
This is an Open Access work distributed under the terms of the Creative Commons Attribution 3.0 Unported License (http://creativecommons.org/licenses/by/3.0/).
